Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aegerion Pharmaceuticals provides update on lomitapide NDA

March 12, 2012

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

March 9, 2012

New diacylglycerol O-acyltransferase 1 inhibitors reported by Merck & Co.

March 8, 2012

Plant-derived lactic acid bacteria may help combat obesity

March 8, 2012

Novel tablet for type 2 diabetes available in U.S. pharmacies

March 8, 2012

Roche discovers new HSL inhibitors

March 8, 2012

New sodium/glucose cotransporter 2 inhibitors developed in China

March 8, 2012

Madrigal launches new phase I trial of cholesterol-lowering agent

March 7, 2012

Advinus Therapeutics announces novel glucokinase activators

March 7, 2012

FDA issues complete response letter for ezetimibe/atorvastatin tablets

March 6, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...